Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BIO Conference

POZEN, Inc. (POZN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

POZEN is a progressive pharmaceutical company focused on transforming the way unmet medical needs are addressed by the healthcare industry. POZEN has successfully developed two self-invented products in two years, receiving FDA approval for both. Utilizing the funding from these … Continue reading

Posted in BIO Conference | Leave a comment

OXiGENE, Inc. (OXGN) Starts Presentation at 15th Annual BIO CEO & Investor Conference

OXiGENE is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for treating cancer, with its primary focus on developing vascular disrupting agents that selectively disrupt abnormal blood vessels that are associated with solid tumor progression. The company … Continue reading

Posted in BIO Conference | Leave a comment

Idenix Pharmaceuticals, Inc. (IDIX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Idenix Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of human viral diseases. The company’s focus is currently on treating patients with hepatitis C infection. Building on its expertise in nucleoside chemistry … Continue reading

Posted in BIO Conference | Leave a comment

OncoSec Medical, Inc. (ONCS) Starts Presentation at 15th Annual BIO CEO & Investor Conference

OncoSec Medical is a biopharmaceutical company focused on developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for treating solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform that dramatically enhances … Continue reading

Posted in BIO Conference | Leave a comment

Soligenix, Inc. (SNGX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Soligenix is a development-stage biopharmaceutical company engaged in developing products for the treatment of serious inflammatory diseases with unmet medical need. The company is developing several biodefense vaccines and therapeutics as well as proprietary formulations of oral BDP for the … Continue reading

Posted in BIO Conference | Leave a comment

Newron Pharmaceuticals S.p.A. (NWPHF) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Newron Pharmaceuticals is a biopharmaceutical company with its focus on novel therapies for central nervous system diseases and pain. Currently, Phase III trials of safinamide are ongoing for the treatment of Parkinson’s disease, which Merck Serono has exclusive global rights … Continue reading

Posted in BIO Conference | Leave a comment

GeoVax Labs, Inc. (GOVX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

GeoVax Labs is a biotechnology company focused on the development of vaccines for diseases caused by HIV. The company’s vaccines are unique in expressing virus-like particles displaying the trimeric membrane-bound form of the HIV-1 envelope glycoprotein. Presently in Phase I … Continue reading

Posted in BIO Conference | Leave a comment

EpiCept Corp. (EPCT) Starts Presentation at 15th Annual BIO CEO & Investor Conference

EpiCept is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to treat pain and cancer. The company’s cancer product, Ceplene, has been approved in the European Union, and its balanced pipeline of three major clinical product candidates … Continue reading

Posted in BIO Conference | Leave a comment

Alnylam Pharmaceuticals, Inc. (ALNY) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Alnylam Pharmaceuticals is a biopharmaceutical company engaged in developing novel therapeutics based on RNA interference (RNAi). The company is at the helm of translating RNAi into a new class of innovative medicines, with a core focus on RNAi therapeutics for … Continue reading

Posted in BIO Conference | Leave a comment

Transcept Pharmaceuticals, Inc. (TSPT) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Transcept Pharmaceuticals is a specialty pharmaceutical company engaged in developing and commercializing proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the company’s first FDA-approved product. Commercialization and development rights … Continue reading

Posted in BIO Conference | Leave a comment